FDA's 503B GLP-1 Exclusion Proposal: Comment Period Closed, Final Determination Pending — What Research Procurement Teams Should Know

Key takeaways

• On 30 April 2026, the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, citing no demonstrated clinical need for large-scale outsourcing-facility compounding of these agents.
• The public comment period closed on 29 June 2026; the agency is now reviewing submissions before issuing a final determination.
• If finalised, the rule would close the last remaining legal pathway for 503B outsourcing facilities to compound these GLP-1 receptor agonists from bulk API outside of an FDA-declared shortage.
• The 503A patient-specific route remains legally separate but cannot operate at comparable scale.
• For UK research laboratories, the practical consequence is a narrowing supply chain for regulated, large-scale compounded GLP-1 API — a consideration that affects procurement of reference standards and experimental material.

Background: what the 503B Bulks List is and why it matters

Under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), FDA-registered outsourcing facilities — large-scale compounders that operate under current good manufacturing practice (cGMP) standards — may compound drugs from bulk active pharmaceutical ingredients (API) only when those ingredients appear on the 503B Bulks List, or when the drug appears on FDA's official shortage list at the time of compounding, distribution, and dispensing. FDA.gov

The 503B framework is distinct from the 503A route, which governs patient-specific compounding by licensed pharmacies operating under state board oversight. Alliance for Pharmacy Compounding / CNN The 503B channel was the mechanism that enabled large-volume compounded GLP-1 supply during the shortage years, when branded product was unavailable at sufficient scale to meet demand.

The GLP-1 shortage window and its closure

Semaglutide products were placed on the FDA drug shortage list in 2022 and removed in February 2025; tirzepatide was added in 2022 and its shortage was resolved in late 2024. Removal from the shortage list eliminated the primary legal basis for large-scale compounding of these agents by 503B outsourcing facilities. That left open the question of whether the compounds might nonetheless be added to the 503B Bulks List via nomination — a pathway that would have allowed compounding independent of shortage status.

The FDA evaluated nominations for all three substances and concluded it had not identified sufficient evidence to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, stating that "a determination of clinical need is based on patient safety and medical necessity under the law." The agency published a notice of proposed rulemaking in the Federal Register on 1 May 2026 (Docket 2026-08552), formally initiating the exclusion process.

If finalised, this would foreclose bulk API compounding of these GLP-1 receptor agonists by 503B outsourcing facilities outside of an FDA-declared shortage. The FDA explicitly rejected affordability and insurance access arguments as grounds for establishing clinical need, according to analysis of the Federal Register notice by healthcare regulatory specialists at onhealthcare.tech.

The adversarial context: warning letters and legal challenges

The exclusion proposal did not emerge in isolation. The FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide as of early 2025, many involving dosing errors from patients self-administering from multidose vials — some of which required hospitalisation. The agency cited these figures in its enforcement rationale.

Separately, concerns about counterfeit and adulterated products entering the market through online channels reinforced the FDA's posture. The Outsourcing Facilities Association pursued legal challenges but failed to secure preliminary injunctions, establishing that "essentially a copy" compounding of semaglutide or tirzepatide was impermissible under 503A and 503B. The legal landscape has therefore progressively narrowed since the shortage resolutions.

Liraglutide injection remains on the shortage list as of mid-2026, meaning 503B outsourcing facilities can still compound it during that period despite its absence from the 503B Bulks List — but that exception depends on shortage status persisting.

Where the process stands now

The public comment period closed on 29 June 2026. The FDA will consider all submitted public comments before making a final determination on the status of these substances. No timeline for a final rule has been publicly confirmed, though regulatory analysts at Pharmacy Times noted that the proposal's framing — and the FDA's consistent enforcement posture — signals that "large-scale compounding of these agents has no regulatory future." Pharmacy Times

The comment review phase typically precedes a final rule publication in the Federal Register, after which the prohibition would come into force on a specified compliance date. In parallel, the 503A patient-specific compounding route for these agents remains legally distinct, but 503A facilities cannot replicate the volume or scale of 503B outsourcing operations.

Implications for research procurement in the UK

For UK-based research institutions, the 503B exclusion trajectory carries several practical considerations.

Reference standards and API sourcing. Research programmes using semaglutide, tirzepatide, or liraglutide as experimental comparators or reference materials have historically had access to compounded API from 503B outsourcing facilities as a lower-cost or more flexible alternative to branded product. Finalisation of the exclusion rule will progressively close that channel. Procurement teams should assess whether current stock levels and existing supplier agreements are sufficient to bridge the period pending a final determination, and should identify certified reference standard suppliers operating under European or international pharmacopoeial standards.

Quality differentiation. The FDA's adverse event data and the concerns around salt-form variations — compounders have at times used semaglutide sodium rather than the free-acid form tested in clinical trials, and the two formulations have not been shown to be bioequivalent — reinforce the case for sourcing from suppliers who can provide full analytical characterisation, including HPLC purity data and mass spectrometry confirmation of molecular identity and salt form.

503B vs 503A distinction in UK context. The 503B/503A framework is specific to US law and has no direct equivalent under MHRA regulation. However, the underlying regulatory logic — distinguishing between patient-specific, small-volume compounding and large-scale outsourced manufacture — maps broadly onto the MHRA's own tiered approach to specials and unlicensed medicines. UK labs sourcing from US-based suppliers should ascertain whether those suppliers operate under 503B or 503A frameworks, as the compliance obligations and scale differ materially.

Parallel pricing pressure. During the shortage period, compounded GLP-1s reached approximately 30% of total US supply at peak in 2024, priced at roughly $150–$300 per month versus more than $1,000 for branded product. As that channel closes, cost pressure will shift back toward branded API or synthetic research-grade sources. Budgeting assumptions for multi-year GLP-1 research programmes should be revised accordingly.

What remains to be determined

Several questions remain unresolved pending the FDA's final determination:

1. Timeline. The agency has not committed to a publication date for the final rule. Given the volume of public comments expected — the GLP-1 compounding debate attracted significant stakeholder engagement — review may extend into late 2026 or beyond.

2. Shortage re-declaration risk. Finalisation of the exclusion does not prevent re-opening of the compounding pathway if a new shortage were to be declared for any of the three agents. The current rule specifically preserves shortage-list compounding as an exception.

3. 503B and 503A interaction. Future PCAC advisory meetings may choose to incorporate discussion of 503B authorities in the context of peptide compounding more broadly — a development that could reintroduce questions about GLP-1 analogues or investigational peptide-GLP-1 combinations into the 503B framework.

Research-procurement teams with active GLP-1 programmes should monitor the Federal Register for publication of the final determination and review supplier agreements before it takes effect.